The crucial role of these molecules in tumor immune evasion has led to the development of anti-programmed cell death protein 1 (PD-1) and anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) therapies for cancer. This evidence concerns the gene PDCD1 and neoplasm.